1. In Vivo

Development Versus Dealmaking: How To Obtain A Blockbuster

 
• By Elizabeth Cairns, Jessica Merrill, and In Vivo Team

Most of the companies with blockbuster drugs approved over the past decade oversaw their clinical development internally. Lilly holds the lead with eight blockbusters developed in-house.  

Discovery Versus Dealmaking
• Source: Shutterstock

Considering that an actual or potential blockbuster developed by a smaller biotech is catnip to big pharma, obtaining a blockbuster by buying it might be expected to be the most common strategy. But according to data from Evaluate, only 81 companies with blockbusters gained them through dealmaking – at least when the parameters are limited to clinical stages.

Meanwhile, 105 drug companies either discovered blockbusters internally or bought them before clinical trials had started

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

More from In Vivo

Plans For London Cancer Hub Promises New Destination For Biotech Innovation

 
• By Jo Shorthouse

Plans have been submitted for a £1bn development in London that can home biotech companies and encourages cross collaboration with the Institute of Cancer Research. In Vivo took an exclusive tour of the UK’s prospective new cancer innovation district.

Califf In Conversation: “Decimated” FDA Teams Endanger Biologics Progress

 
• By Barnaby Pickering

In Vivo spoke to the previous commissioner of the US FDA about recent ongoings at the agency, and where he believes policy should be directed for patient and industry benefit.

Rising Leaders 2025: Rob Barrow On Leading MindMed’s Psychedelic Renaissance

 
• By Jo Shorthouse

Rob Barrow's unconventional journey from finance to leading MindMed highlights his innovative approach to psychedelic medicine, aiming to transform mental health treatment with groundbreaking therapies.